



11 December 2009

Immunodiagnostic Systems Holdings plc

Appointment of Non-Executive Director

Immunodiagnostic Systems Holdings plc (“IDS”), a leading producer of diagnostic testing kits for the clinical and research markets, announces the appointment of Dr. Patrik Olof Dahlén as a Non-Executive Director with immediate effect.

Dr. Dahlén, aged 47, has over 20 years of experience in the diagnostics and life science industries and recently became Chief Executive Officer of Chempaq A/S, the Denmark-based Point of Care diagnostics company (www.chempaq.com) in November 2009.

Previously Dr. Dahlén was CEO of Dako A/S having joined the Denmark based company in 2005. During this time he repositioned the company as a global leader in cancer and companion diagnostics leading up to its sale to EQT, a private equity company, in 2007. Before joining Dako, Dr. Dahlén was CEO of BiImage A/S from 2001.

Earlier in his career Dr. Dahlén moved from research through to international senior management positions within Wallac (now part of PerkinElmer Inc.), becoming Senior Vice President of PerkinElmer Inc and holding the role of President at PerkinElmer Life Sciences Inc. He has a Ph.D. in Biochemistry from Turku University in Finland.

Dr. Dahlén also serves as Chairman of OLink Biosciences (Uppsala, Sweden) and has been a board member of several companies including Cantion and DakoCytomation, both in Copenhagen and DxS Diagnostics in Manchester, UK.

David Evans, Chairman of IDS, said, *“We are very pleased to appoint Patrik to the Board. Patrik has huge international experience in the diagnostic sector with both large and instrument based IVD companies and will be invaluable to the IDS Board as it continues to execute its growth plans.”*

Aim Rules Disclosures:

Current Directorships

Chempaq A/S
DxS Diagnostics Ltd
OLink AB
Proxeon A/S

Previous Directorships (last five years)

BiImage A/S
Cantion A/S
DakoCytomation A/S
Dako A/S

There are no further matters in connection with the appointment of Dr. Dahlén to be disclosed under Schedule Two, paragraph (g) of the AIM Rules.

Enquiries:

Immunodiagnostic Systems Holdings Plc

David Evans, Chairman
Roger Duggan, CEO

Tel: 0191 519 0660

Brewin Dolphin Investment Banking

Andrew Emmott
Sean Wyndham-Quin

Tel: 0845 213 4730

Walbrook PR Ltd

Paul McManus

Tel: 020 7933 8787
Mob: 07980 541 893

paul.mcmanus@walbrookpr.com